Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Next Previous
Trial Profile

A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Acronyms PIONEER-OLE
  • Sponsors Abbott Laboratories; AbbVie

Most Recent Events

  • 02 Apr 2021 Results assessing Baseline and week 12 plasma samples from the PIONEER studies were used to assess the levels of circulating proteins by multiplex assays and enzyme linked immunosorbent assays published in the British Journal of Dermatology
  • 02 Nov 2018 According to an AbbVie media release, results from this study were presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
  • 31 May 2018 Results published in the Journal of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top